z-logo
Premium
Multifactorial analysis of parameters influencing chemosensitivity of human cancer xenografts in nude mice
Author(s) -
Fujita Fumiko,
Fujita Masahide,
Taguchi Tetsuo,
Shimozuma Kojiro,
Sakamoto Yasuo,
Kimoto Yasuhiko,
Hirai Toshihiro
Publication year - 1989
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.2910430417
Subject(s) - mitomycin c , chemotherapy , cancer , doxorubicin , breast cancer , medicine , pathology , cancer research , surgery
Abstract The results of single‐agent chemotherapy, with 11 anti‐cancer agents, of 15 human gastro‐intestinal and breast cancer lines xenografted into nude mice indicate inherent individuality of chemosensitivity spectrum of each tumor. The following 9 parameters have been measured as factors possibly relevant to chemosensitivity of tumor tissue or tumor‐bearing mice: grade of histological differentiation, vascularity, percentage of necrosis, VDT, 3 H‐thymidine LI, human LDH activity in the cancer tissue, tissue/serum LDH ratio, TdR Pase activity, and serum CEA. These parameters exhibited presumably constant values for each tumor line. Chemosensitivity, i.e. , inhibition of tumor growth by a given drug, was used as the dependent variable, and values of the 9 parameters in each cancer as the explanatory variables. Multiple regression analyses with stepwise deletion were performed for each of the 11 drugs. The equations for 8 drugs exhibited coefficients of determination of over 70%, and in particular those for M‐83 (a derivative of mitomycin C), nimustine hydrochloride and doxorubicin exceeded 80% by equations with 3–4 parameters. Consequently, the estimated value for each line of effectiveness derived from the equations for these 8 drugs showed remarkable coincidences with the actual values for the inhibition rates of the corresponding drugs.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here